Results 131 to 140 of about 2,211,903 (315)

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects

Scientific Reports
This study aimed to evaluate the bioequivalence between test and reference insulin degludec (IDeg) and the effects of body composition on pharmacokinetics and pharmacodynamics of IDeg in Chinese healthy volunteers.
Rui Su, Lei Wan, Yi Tao, Mingxue Zhu, Junliang Pu, Zhongping Li, Yuan Chen, Chengyong Tang   +7 more
doaj   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

Frontiers in Pharmacology
IntroductionSuraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07, which inhibits influenza viral replication by targeting cap-dependent endonuclease through a single oral dose.
Mai Han, Gang Cui, Yan Zhao, Xianbo Zuo, Xiaoxue Wang, Xin Zhang, Na Mi, Jiangli Jin, Chunyan Xiao, Jing Wang, Wei Wu, Yajuan Li, Jintong Li   +12 more
doaj   +1 more source

Industry sponsored oncology clinical trials

, 2009
The US clinical trial register data was analysed to characterise industry and partially non-industry sponsored oncology clinical trials. The analysis found 2,248 trials with 45,882 study sites and 420,378 study subjects for industry-sponsored oncology ...
Yao, TJ, Karlberg, JPE, Yau, HKC
core  

Nurturing the Clinical Research Leaders of Tomorrow

, 2010
Well-designed and performed pivotal trials are critical in providing the efficacy and safety of a new drug for regulatory approval. The success of clinical drug development relies oil the ability of clinical trial leaders to design and conduct ...
汪志雄;陳恆德, Chuang, Feng-Pin; Chan, Wing-Kai; Chen, Min-Hui; Chang, Yen-Huei; Wong, Chih-Shung; Chern, Herng-Der   +1 more
core   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects

Frontiers in Pharmacology
BackgroundMefunidone is a novel synthetic compound and is better when compared to pirfenidone for the anti-fibrotic treatment of renal fibrosis in end-stage renal disease.
Mai Han, Bishan Huo, Gaoyun Hu, Xin Zhang, Gang Cui, Wei Wu, Na Mi, Shixi Zhang, Jiangli Jin, Xing Lu, Bidong Wu, Chunyan Xiao, Jing Wang, Zheng Bian, Jintong Li   +14 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Drugs in R&D
Background and Objective Azithromycin is the first azalide antibiotic that is related to the macrolide family of antibiotics. Bioequivalence studies in China are initiated by the National Medical Products Administration (NMPA), which supports a generic ...
Yingrong Chen, Libing Ye, Jue Mei, Mengli Tian, Min Xu, Qiuyue Jin, Xiang Yu, Shuixin Yang, Jie Wang   +8 more
doaj   +1 more source